Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03275103 trial: what clinicians have said so far
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- NCT03275103 ↗
- Completed
- Genentech, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03275103 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03275103 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab; Tocilizumab
- Arms
- Arm A: Single Step Dose Escalation for Cevostamab · Experimental
- Arm B: Double Step Dose Escalation for Cevostamab · Experimental
- Arm C: Single Step Dose Expansion for Cevostamab · Experimental
- Arm D: Double Step Dose Expansion for Cevostamab · Experimental
- Arm E: Expansion Phase for Tocilizumab Pretreatment · Experimental
- Arm F: Single Step Dose Expansion for Cevostamab · Experimental
- Arm G: Double Step Dose Expansion for Cevostamab · Experimental
- Arm H: Triple Step Dose Escalation for Cevostamab · Experimental
- Arm I: Triple Step Dose Expansion for Cevostamab · Experimental
- Arm J: Expansion Phase for Tocilizumab Pretreatment · Experimental
- Arm K: Compressed Double Step Dose Expansion for Cevostamab · Experimental
- Enrollment
- 355
- Primary outcomes
- Percentage of Participants with Adverse Events (AEs)
- Percentage of Participants With Dose-Limiting Toxicities (DLTs)
- Arms E and J Only: Incidence and Severity of Cytokine-release Syndrome (CRS) Following Tocilizumab Premedication Followed by Treatment with Cevostamab
- Sponsor
- Genentech, Inc.
- Start
- Sep 19, 2017
- Primary completion
- Jan 7, 2026
- Results posted
- No
- Registry record
- NCT03275103 · updated Feb 5, 2026
Publications
linked from the registry- Cohen AD, Richter J, Trudel S, Lesokhin A, Laubach JP, Thomas SK, Harrison SJ, Costa LJ, Spencer A, Fonseca R, Forsberg PA, Berdeja JG, Kaedbey R, Bahlis NJ, Rodriguez-Otero P, Mateos MV, Tyagi T, Samineni D, Liu W, Nakamura R, Choeurng V, Wong C, Cooper J, Krishnan A. FcRH5xCD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med. 2026 Aug;32(8):2909-2917. doi: 10.1038/s41591-026-04522-3. Epub 2026 Jul 22. PubMed 42487061